{"id":"W1892175722","doi":"10.1111/bjd.14018","title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials","year":2015,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":322,"is_retracted":false,"has_abstract":true,"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"Janssen Biotech; Allergan; LEO Pharma; Genentech; Celgene; Novartis; Pfizer; ApoPharma; Boehringer Ingelheim; Amgen; AbbVie; Merck; Abbott Laboratories; Eli Lilly and Company","keywords":"Tofacitinib; Janus kinase inhibitor; Placebo; Medicine; Adverse effect; Psoriasis; Internal medicine; Randomized controlled trial; Plaque psoriasis; Gastroenterology; Dermatology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002484956,0.000380056,0.003613719,0.0001903899,0.0002268486,0.0000517182,0.0003823239,0.000401863,0.0001033978],"category_scores_gemma":[0.001691588,0.0002631405,0.001206783,0.0001041225,0.0004169327,0.0002170349,0.00002578108,0.0002032258,0.00001818295],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001468696,"about_ca_system_score_gemma":0.0006430022,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001029357,"about_ca_topic_score_gemma":0.000809523,"domain_scores_codex":[0.9927218,0.003575011,0.002752978,0.0003454118,0.0001110754,0.0004937213],"domain_scores_gemma":[0.9909625,0.00597903,0.002150761,0.0003444234,0.0004340119,0.0001292874],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7638176,0.001957686,0.00003056512,0.000007236606,0.005589402,0.0008169835,0.001167018,0.00004540032,0.00252511,0.00009976768,0.004622989,0.2193202],"study_design_scores_gemma":[0.9044455,0.002230152,0.000009226125,0.0001020741,0.003733391,0.008416018,0.0006252618,0.00007546736,0.05510736,0.0004545917,0.02456955,0.0002313967],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8934438,0.09621257,0.001090101,0.0007736578,0.004045515,0.002393753,0.001920657,0.00002791039,0.0000920594],"genre_scores_gemma":[0.9914985,0.006278812,0.0004043989,0.0000533435,0.0007570318,0.0002701262,0.0005098314,0.00003228597,0.0001956421],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2190888,"threshold_uncertainty_score":0.9999821,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04869677487528288,"score_gpt":0.3168638201301229,"score_spread":0.26816704525484,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}